EVO ▼ -3.2% - Evotec SE $EVO - Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors Evotec shares fell 3.2% despite announcing a new research collaboration with Plectonic to develop T-cell-engaging therapies for solid tumors. The decline suggests investors may have been disappointed by the scope or terms of the partnership, or viewed the announcement as insufficient to offset broader market concerns about the company's pipeline or financial outlook. 02-SEP-2026 02:05 AM ET